Wide Ranks

JAZZ

Jazz Pharmaceuticals plc

122.64

Top Statistics
Market Cap 7 B Forward PE 5.62 Revenue Growth 8.50 %
Current Ratio 4.26 Trailing PE 17.37 Earnings Growth 59.70 %
Profit Margins 11.60 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 7.24 Enterprise / Revenue 2.75 Price To Sales Trailing12 Months 1.86
Profitability
Profit Margins 11.60 % Operating Margins 24.67 %
Balance Sheet
Total Cash 2 B Total Cash Per Share 43.31 Total Debt 6 B
Total Debt To Equity 148.75 Current Ratio 4.26 Book Value Per Share 69.01
All Measures
Short Ratio 566.00 % Message Board Id finmb_6724933 Shares Short Prior Month 3 M
Return On Equity 0.1209 City Dublin Uuid f94e4ce5-31cc-3ee5-a798-7a51cf96cf30
Previous Close 122.79 First Trade Date Epoch Utc 1 B Book Value 69.01
Beta 0.5730 Total Debt 6 B Volume 270816
Price To Book 1.78 Fifty Two Week Low 99.06 Total Cash Per Share 43.31
Total Revenue 3 B Shares Short Previous Month Date 1 B Target Median Price 182.00
Audit Risk 8 Max Age 86400 Recommendation Mean 1.80
Sand P52 Week Change 0.3133 Operating Margins 24.67 % Target Mean Price 177.53
Net Income To Common 463 M Short Percent Of Float 0.0841 Implied Shares Outstanding 60 M
Trailing Peg Ratio 90.83 % Last Fiscal Year End 1 B Average Daily Volume10 Day 672080
Average Volume10days 672080 Total Cash 2 B Next Fiscal Year End 1 B
Revenue Per Share 64.04 Held Percent Insiders 0.0294 Ebitda Margins 38.03 %
Trailing PE 17.37 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 3 Regular Market Previous Close 122.79 Target Low Price 128.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 114.43 Open 123.73
Free Cashflow 1 B Dividend Yield 0.00 % Return On Assets 0.0462
Time Zone Short Name EST Board Risk 3 Trailing Eps 7.06
Day Low 121.80 Address1 Waterloo Exchange Shares Outstanding 60 M
Compensation Risk 4 Price Hint 2 Target High Price 230.00
Website https://www.jazzpharma.com 52 Week Change 0.0373 Average Volume 706725
Earnings Quarterly Growth 46.50 % Forward Eps 21.56 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 324.50 % Is_sp_500 False
Regular Market Day High 124.71 Profit Margins 11.60 % Debt To Equity 148.75
Fifty Two Week High 134.17 Day High 124.71 Shares Short 3 M
Regular Market Open 123.73 Industry Key biotechnology Earnings Growth 59.70 %
Enterprise To Revenue 2.75 Revenue Growth 8.50 % Shares Percent Shares Out 0.0631
Operating Cashflow 1 B Currency USD Time Zone Full Name America/New_York
Market Cap 7 B Is_nasdaq_100 False Zip D04 E5W7
Quote Type EQUITY Industry Biotechnology Long Name Jazz Pharmaceuticals plc
Overall Risk 3 Regular Market Day Low 121.80 Held Percent Institutions 0.9880
Current Price 122.64 Address2 Fifth Floor Waterloo Road Enterprise To Ebitda 7.24
Financial Currency USD Current Ratio 4.26 Gross Margins 92.62 %
Industry Disp Biotechnology Number Of Analyst Opinions 19 Country Ireland
Float Shares 58 M Two Hundred Day Average 112.90 Governance Epoch Date 1 B
Ir Website http://investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-irhome Price To Sales Trailing12 Months 1.86 Enterprise Value 11 B
Forward PE 5.62 Regular Market Volume 270816 Ebitda 1 B
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally.

The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders.

The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders.

The company was incorporated in 2003 and is headquartered in Dublin, Ireland.